Table 1. Patients' characteristics.
| Factor | Total (n=97) | Expressing a class I ligand in the recipient for donor-inhibitory KIR (n=23) | Lacking a class I ligand in the recipient for donor-inhibitory KIR (n=74) | P-value |
|---|---|---|---|---|
| Median age at transplantation, years old (range) | 28 (7–57) | 33 (15–54) | 26 (7–57) | 0.081 |
| Male sex, no. (%) | 68 (70%) | 15 (65%) | 53 (72%) | 0.558 |
| Diagnosis, no. (%) | 0.157 | |||
| CP1 | 50 (52%) | 11 (48%) | 39 (53%) | |
| CP2 | 15 (15%) | 9 (39%) | 15 (20%) | |
| AP | 24 (25%) | 3 (13%) | 12 (16%) | |
| BC | 8 (8%) | 0 (0%) | 8 (11%) | |
| Donor/patient sex, no. (%) | 0.128 | |||
| F/M | 34 (35%) | 4 (17%) | 30 (41%) | |
| F/F | 15 (16%) | 5 (22%) | 10 (14%) | |
| M/M | 32 (33%) | 11 (48%) | 21 (28%) | |
| M/F | 16 (17%) | 3 (13%) | 13 (18%) | |
| HLA matching, no. (%) | 0.328 | |||
| 3/6 | 9 (9%) | 2 (9%) | 7 (10%) | |
| 4/6 | 33 (34%) | 5 (22%) | 28 (38%) | |
| 5/6 | 55 (55%) | 16 (70%) | 39 (53%) | |
| Median infused TNC, × 109 per kg | 7.07 (2.89–14.12) | 7.25 (5.24–13.38) | 6.94 (2.89–14.12) | 0.292 |
| Median infused CD34+, × 106 per kg | 2.18 (0.44–9.52) | 2.05 (0.65–9.52) | 2.28 (0.44–7.46) | 0.594 |
| Median infused CD3+, × 108 per kg | 1.48 (0.2–5.10) | 1.48 (0.23–2.89) | 1.54 (0.20–5.10) | 0.973 |
| Median follow-up among survivors, years (range) | 6.7 (3.6–10.1) | 6.9 (3.7–9.6) | 6.8 (3.6–10.1) | 0.113 |
|
Engraftment | ||||
| WBC, median days (range) | 13.5 (10–25) | 14 (11–21) | 13 (10–25) | 0.212 |
| PLT, median days (range) | 16 (9–188) | 18 (9–188) | 16 (9–151) | 0.282 |
| Presence of HLA-C2 in recipients of donor-KIR2DS1 | 15 (16%) | 9 (39%) | 6 (8%) | <0.01 |
| Presence of HLA-Bw4 in recipients of donor-KIR3DS1 | 19 (20%) | 10 (44%) | 9 (12%) | <0.01 |
| Presence of HLA-C2 or HLA-BW4 in recipients of donor-KIR2DS1 or -KIR3DS1 | 25 (26%) | 11 (48%) | 14 (19%) | 0.01 |
| Accepted TKI therapy post-transplantation | 15 (15%) | 0 (0%) | 15 (20%) | 0.019 |
| Accepted DLI therapy post-transplantation | 14 (14%) | 0 (0%) | 14 (19%) | 0.036 |
Abbreviations: AP=accelerated phase; BC=blast crisis; CP1=chronic phase 1; CP2=chronic phase 2; DLI=donor lymphocyte infusion; F/F=female/female; F/M=female/male; HLA=histocompatibility; M/F=male/female; M/M=male/male; PLT=platelet; TKI=tyrosine kinase inhibitor; TNC=total nuclear cell; WBC=white blood cell.